Cargando…

Can ovarian aging be delayed by pharmacological strategies?

Aging has been regarded as a treatable condition, and delaying aging could prevent some diseases. Ovarian aging, a special type of organ senescence, is the earliest-aging organ, as ovaries exhibit an accelerated rate of aging with characteristics of gradual declines in ovarian follicle quantity and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jinjin, Chen, Qian, Du, Dingfu, Wu, Tong, Wen, Jingyi, Wu, Meng, Zhang, Yan, Yan, Wei, Zhou, Su, Li, Yan, Jin, Yan, Luo, Aiyue, Wang, Shixuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366956/
https://www.ncbi.nlm.nih.gov/pubmed/30674710
http://dx.doi.org/10.18632/aging.101784
_version_ 1783393697541390336
author Zhang, Jinjin
Chen, Qian
Du, Dingfu
Wu, Tong
Wen, Jingyi
Wu, Meng
Zhang, Yan
Yan, Wei
Zhou, Su
Li, Yan
Jin, Yan
Luo, Aiyue
Wang, Shixuan
author_facet Zhang, Jinjin
Chen, Qian
Du, Dingfu
Wu, Tong
Wen, Jingyi
Wu, Meng
Zhang, Yan
Yan, Wei
Zhou, Su
Li, Yan
Jin, Yan
Luo, Aiyue
Wang, Shixuan
author_sort Zhang, Jinjin
collection PubMed
description Aging has been regarded as a treatable condition, and delaying aging could prevent some diseases. Ovarian aging, a special type of organ senescence, is the earliest-aging organ, as ovaries exhibit an accelerated rate of aging with characteristics of gradual declines in ovarian follicle quantity and quality since birth, compared to other organs. Ovarian aging is considered as the pacemaker of female body aging, which drives the aging of multiple organs of the body. Hence, anti-ovarian aging has become a research topic broadly interesting to both biomedical scientists and pharmaceutical industry. A marked progress has been made in exploration of possible anti-ovarian agents or approaches, such as calorie restriction mimetics, antioxidants, autophagy inducers etc., over the past years. This review is attempted to discuss recent advances in the area of anti-ovarian aging pharmacology and to offer new insights into our better understanding of molecular mechanisms underlying ovarian aging, which might be informative for future prevention and treatment of ovarian aging and its related diseases.
format Online
Article
Text
id pubmed-6366956
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Impact Journals
record_format MEDLINE/PubMed
spelling pubmed-63669562019-02-15 Can ovarian aging be delayed by pharmacological strategies? Zhang, Jinjin Chen, Qian Du, Dingfu Wu, Tong Wen, Jingyi Wu, Meng Zhang, Yan Yan, Wei Zhou, Su Li, Yan Jin, Yan Luo, Aiyue Wang, Shixuan Aging (Albany NY) Review Aging has been regarded as a treatable condition, and delaying aging could prevent some diseases. Ovarian aging, a special type of organ senescence, is the earliest-aging organ, as ovaries exhibit an accelerated rate of aging with characteristics of gradual declines in ovarian follicle quantity and quality since birth, compared to other organs. Ovarian aging is considered as the pacemaker of female body aging, which drives the aging of multiple organs of the body. Hence, anti-ovarian aging has become a research topic broadly interesting to both biomedical scientists and pharmaceutical industry. A marked progress has been made in exploration of possible anti-ovarian agents or approaches, such as calorie restriction mimetics, antioxidants, autophagy inducers etc., over the past years. This review is attempted to discuss recent advances in the area of anti-ovarian aging pharmacology and to offer new insights into our better understanding of molecular mechanisms underlying ovarian aging, which might be informative for future prevention and treatment of ovarian aging and its related diseases. Impact Journals 2019-01-23 /pmc/articles/PMC6366956/ /pubmed/30674710 http://dx.doi.org/10.18632/aging.101784 Text en Copyright © 2019 Zhang et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY) 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Zhang, Jinjin
Chen, Qian
Du, Dingfu
Wu, Tong
Wen, Jingyi
Wu, Meng
Zhang, Yan
Yan, Wei
Zhou, Su
Li, Yan
Jin, Yan
Luo, Aiyue
Wang, Shixuan
Can ovarian aging be delayed by pharmacological strategies?
title Can ovarian aging be delayed by pharmacological strategies?
title_full Can ovarian aging be delayed by pharmacological strategies?
title_fullStr Can ovarian aging be delayed by pharmacological strategies?
title_full_unstemmed Can ovarian aging be delayed by pharmacological strategies?
title_short Can ovarian aging be delayed by pharmacological strategies?
title_sort can ovarian aging be delayed by pharmacological strategies?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366956/
https://www.ncbi.nlm.nih.gov/pubmed/30674710
http://dx.doi.org/10.18632/aging.101784
work_keys_str_mv AT zhangjinjin canovarianagingbedelayedbypharmacologicalstrategies
AT chenqian canovarianagingbedelayedbypharmacologicalstrategies
AT dudingfu canovarianagingbedelayedbypharmacologicalstrategies
AT wutong canovarianagingbedelayedbypharmacologicalstrategies
AT wenjingyi canovarianagingbedelayedbypharmacologicalstrategies
AT wumeng canovarianagingbedelayedbypharmacologicalstrategies
AT zhangyan canovarianagingbedelayedbypharmacologicalstrategies
AT yanwei canovarianagingbedelayedbypharmacologicalstrategies
AT zhousu canovarianagingbedelayedbypharmacologicalstrategies
AT liyan canovarianagingbedelayedbypharmacologicalstrategies
AT jinyan canovarianagingbedelayedbypharmacologicalstrategies
AT luoaiyue canovarianagingbedelayedbypharmacologicalstrategies
AT wangshixuan canovarianagingbedelayedbypharmacologicalstrategies